Compounds and methods for development of RET modulators

• US 20070066641A1
• Filed: 07/14/2006
• Published: 03/22/2007
• Est. Priority Date: 12/19/2003
• Status: Abandoned Application

• Current Assignee: Plexxikon Inc (Daiichi Sankyo Company Limited)
• Original Assignee: Plexxikon Inc (Daiichi Sankyo Company Limited)
• Inventors: Ibrahim, Prabha, Zuckerman, Rebecca, Habets, Gaston, Artis, Dean
• Application Number:
  US11/487,134
• Publication Number:
  US 20070066641A1
• Time in Patent Office: Days
• US Class Current: 514/300
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

Compounds active on Ret and/or FGFR are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

Claims

1. A method of inhibiting FRS2 interaction with and/or phosphorylation by FGFR in a cell, comprising contacting the cell with an agent that blocks FRS2 interaction with and/or phosphorylation by FGFR, under conditions under which the agent enters the cell.

2. The method of claim 1, wherein the agent is a small molecule compound.

3. The method of claim 2, wherein the agent is a 3-benzoyl-7-azaindole compound.

4. The method of claim 3, wherein the agent is substituted with one or more groups selected from the group consisting of nitro, cyano, hydroxyl, thiol, carboxyl, sulfate, and substituted or unsubstituted amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, ether, thioether, ester, amide, thioester, carbonate, carbamate, urea, sulfonate, sulfone, sulfoxide, sulfonamide, alkyl, alkenyl, alkynyl, acyl, acyloxy, acylamino, aryl, heteroaryl, carbocyclyl, heterocyclyl, aralkyl, hetaralkyl, carbocyclylalkyl, or heterocyclylalkyl.

5. The method of claim 3, wherein the agent is:

optionally further substituted with one or more polar or ionic groups.

6. The method of claim 5, wherein said polar or ionic group is selected from the group consisting of nitro, cyano, hydroxyl, thiol, carboxyl, sulfate, substituted or unsubstituted amino, alkoxy, alkylamino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, ether, ester, amide, carbonate, carbamate, urea, sulfonate, sulfone, sulfoxide, sulfonamide, acyl, acyloxy, and acylamino.

7. The method of claim 1, wherein the agent is formulated with pharmaceutically acceptable carriers.

8. The method of claim 1, comprising administering at least two different types of agents, optionally each having different inhibitory mechanisms.